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Abstract
Background: Thestate of operational tolerance has been detected sporadically in some renal transplanted patients that
stopped immunosuppressive drugs, demonstrating that allograft tolerance might exist in humans. Several years ago, a
study by Brouard et al. identified a molecular signature of several genes that were significantly differentially expressed in the
blood of such patients compared with patients with other clinical situations. The aim of the present study is to analyze the
role of one of these molecules over-expressed in the blood of operationally tolerant patients, SMILE or TMTC3, a protein
whose function is still unknown.
Methodology/Principal Findings: We first confirmed that SMILE mRNA is differentially expressed in the blood of
operationally tolerant patients with drug-free long term graft function compared to stable and rejecting patients. Using a
yeast two-hybrid approach and a colocalization study by confocal microscopy we furthermore report an interaction of
SMILE with PDIA3, a molecule resident in the endoplasmic reticulum (ER). In accordance with this observation, SMILE
silencing in HeLa cells correlated with the modulation of several transcripts involved in proteolysis and a decrease in
proteasome activity. Finally, SMILE silencing increased HeLa cell sensitivity to the proteasome inhibitor Bortezomib, a drug
that induces ER stress via protein overload, and increased transcript expression of a stress response protein, XBP-1, in HeLa
cells and keratinocytes.
Conclusion/Significance: In this study we showed that SMILE is involved in the endoplasmic reticulum stress response, by
modulating proteasome activity and XBP-1 transcript expression. This function of SMILE may influence immune cell
behavior in the context of transplantation, and the analysis of endoplasmic reticulum stress in transplantation may reveal
new pathways of regulation in long-term graft acceptance thereby increasing our understanding of tolerance.
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Introduction
The routine monitoring of renal allograft survival in humans
depends on functional clinical parameters such as blood creatinine
clearance, proteinuria level, the presence of circulating anti-HLA
and donor specific antibodies and scoring of intra-graft lesions in
graft biopsies. Standard immunosuppressive drugs are non-
specific, increase opportunistic infections and malignancies and
can be nephrotoxic [1]. Immune tolerance, which has been
achieved in several experimental models [2], might provide a
means of avoiding such inherent problems since immunosuppres-
sive treatment could be reduced or completely withdrawn in
tolerant patients. Although this phenomenon (induced or ‘‘spon-
taneous’’) is rare in renal transplantation in primates and humans,
several studies have shown its clinical feasibility [3,4,5]. Identifying
and understanding the biological features characterizing opera-
tional tolerance may unveil molecular mechanisms allowing such
patients to tolerate their graft without immunosuppression
treatment. We previously identified 49 genes differentially
expressed in the blood of operationally tolerant patients compared
to stable patients under classical immunosuppressive therapy,
patients with chronic antibody-mediated rejection and healthy
volunteers [6]. These genes were shown to be able to correctly
classify most of the patients according to their clinical status.
Among these genes, we focused on SMILE, also called TMTC3
(transmembrane and tetratricopeptide repeat containing 3 pro-
tein), because it was one of the 13 genes that were over-expressed
in the blood of operationally tolerant patients and because its
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(NM_181783) and a 914 amino acid transmembrane protein
(NP_861448). The protein presents the particularity of 10
tetratricopeptide repeats (TPRs, according to the UniProtKB
website, http://www.uniprot.org/uniprot/Q6ZXV5), a pattern
ubiquitously conserved through evolution and species. TPR-
containing proteins are involved in several cellular functions such
as molecular chaperone complexes, anaphase promoting com-
plexes, transcription repression complexes, protein import com-
plexes and protein folding [7]. They are found in a variety of
different organisms and in various sub-cellular locations such as
the cytosol, nucleus, mitochondria and peroxisomes [7]. The
involvement of these motifs and the importance of their
interactions for molecular and cellular functions have thus been
shown in a number of different biological systems [7].
The aim of our study was to analyse the cellular and molecular
function of SMILE/TMTC3 in vitro and the global pathways in
which it is involved. In this study we report that SMILE interacts
with PDIA3, a molecule involved in protein folding, and is
involved in response to endoplasmic reticulum (ER) stress, which
may play a role in immune regulation.
Results
SMILE transcripts are differentially expressed in PBMCs
from operationally tolerant kidney transplant patients
compared to stable patients and patients with chronic
antibody-mediated rejection
In order to confirm the previous finding of SMILE mRNA
differential expression in the blood of operationally tolerant
patients compared to stable and chronic rejection patients by
microarrays [6], SMILE mRNA levels were analyzed in the
PBMCs of healthy volunteers (HV, n=11), operationally tolerant
patients (TOL, n=8), and patients under standard immunosup-
pressive therapy with either stable graft function (STA, n=9) or
deteriorating graft function with biopsy-proven chronic antibody-
mediated rejection (CAMR, n=14). As shown in Figure 1A,
SMILE mRNA was significantly differentially expressed in the
PBMCs of TOL patients compared with STA (**p,0.01) and
CAMR patients (*p,0.05) (Kruskal-Wallis test, p=0.0205). The
difference in transcript expression in the PBMCs of operationally
tolerant patients was also confirmed compared to a larger cohort
of patients with chronic rejection (19 patients) and a larger cohort
of stable patients (164 patients) (Figure S1). The capacity of
SMILE transcripts to distinguish between operationally tolerant
patients and stable patients (Figure 1B) was studied by receiver
operating characteristic (ROC) curve analysis. This analysis
revealed a very good discriminative power for SMILE to
distinguish TOL patients from STA patients with an optimal
threshold of 1.23 (area under the curve [AUC]=0.98; 95%
confidence interval 0.95 to 1, good sensitivity of 1 and good
specificity of 0.93). A ROC curve analysis also determined that the
capacity of SMILE transcripts to distinguish between operationally
tolerant patients and patients with chronic antibody-mediated
rejection was also very good, with an optimal threshold of 1.86
(area under the curve [AUC]=0.83; 95% confidence interval 0.66
to 0.96, good sensitivity of 0.77 and good specificity of 0.75)
(Figure S2).
Furthermore, in a homogeneous cohort of 164 stable patients
with a well characterized clinical status: stable renal function
(STA) for more than five years under standard immunosuppressive
therapy (thirty percent of these stable patients under Prograf and
seventy percent under Cyclosporin A treatment), we showed that
the level of SMILE mRNA was independent of quantitative
variables, including time post-transplantation, creatinine clear-
Figure 1. SMILE mRNA profile in renal transplant patients. (A) SMILE mRNA transcripts were increased in the PBMC of operationally tolerant
patients (TOL, n=8) compared to patients with stable graft function under standard immunosuppressive therapy (STA, n=9, **p,0.01) and
deteriorating graft function under standard immunosuppressive therapy with biopsy-proven chronic antibody-mediated rejection (CAMR, n=14,
*p,0.05)( * p=0.0205, Kruskal-Wallis test,). (B) The ROC curve measuring the ability of SMILE mRNA quantity to correctly classify operationally tolerant
patients versus patients with stable function.
doi:10.1371/journal.pone.0019321.g001
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age (Figure S3). Similarly, SMILE mRNA levels were also shown
to be independent of qualitative variables (described as frequen-
cies) such as recipient and donor gender, presence of anti-HLA
antibodies or types of immunosuppressive treatment (Figure S4).
Together, these results suggest that SMILE may be a good
biomarker of transplant status.
SMILE is involved in protein metabolism
SMILE was identified as a high confidence prey (Predicted
Biological Score A [8]) in a yeast two hybrid screen with Protein
Disulfide Isomerase family A member 3 (PDIA3 or GRP58) as
bait, performed on a random-primed human brown adipocyte
cDNA library (Figure S5). PDIA3 is involved in the folding of
glycoproteins by disulfide bond formation in the ER and is over-
expressed in ER stress [9]. Double-staining of SMILE and PDIA3
in odontoblast cultures (Figure 2C and D) also showed that
SMILE and PDIA3 colocalized in the endoplasmic reticulum,
confirming that these two molecules can interact in the ER.
To determine the role of SMILE in the cell, we studied SMILE
transcript modulation in the HeLa cell line. SMILE mRNA
expression was checked by RT-PCR and decreased by almost
84% in resting HeLa cells transfected with SMILE siRNA as
compared to cells transfected with the Stealth RNAi negative
control Low GC (Figure S6, ***p=0.0002, Mann-Whitney test,
mean replicate values of three independent experiments). High
throughput microarray analysis was performed on resting HeLa
cells transfected with SMILE or negative control siRNA in order
to identify differentially expressed genes and to define cellular
functions affected by SMILE silencing. Signals were studied with a
SAM analysis (FDR=0.0011, number of permutations: 5000).
Overall, 549 and 532 genes were significantly up- and down-
regulated respectively in cells transfected with SMILE siRNA as
compared to cells transfected with negative control siRNA. Each
list of up-regulated and down-regulated genes was analyzed using
the GOminer website (http://discover.nci.nih.gov/gominer/) to
define enrichment in several key biological functions. In this
approach a function was defined by a GO number. One gene can
have several GO numbers meaning that it can be involved in
several mechanisms. We defined a set of 24 enriched functions for
the list of down-regulated genes (Table 1). This classification was
performed based on GO categories with enrichment p-val-
ues,0.05, and categories with at least 10 differentially expressed
genes among the total genes involved in the function were selected.
Among the down-regulated gene functions of SMILE siRNA-
transfected cells, those concerning protein metabolic processes
(GO:0019538 line 13 Table 1, GO:0044260 line 9 Table 1 and
GO:0044267 line 16 Table 1) were particularly represented, such
as catabolic processes (GO:0009056 line 24 Table 1), proteolysis
(GO:0006508 line 5 Table 1), biopolymer and protein catabolic
processes (respectively GO:0043285 line 12 Table 1 and
GO:0030163 line 10 Table 1). Interestingly, among the down-
regulated transcripts involved in proteolysis, PSMB1 (b1 protea-
some subunit, line 15 in Table 2), PSMB9 (b1i proteasome
subunit, line 17 in Table 2) and PSMB10 (b2i proteasome subunit,
line 10 in Table 2), were found to be significantly down-regulated
after SMILE silencing.
Because SMILE transcript down-regulation decreases tran-
scripts involved in protein degradation, we tested whether SMILE
was involved in proteolysis. We measured the chymotrypsin-like
activity of the proteasome in both SMILE siRNA and control
siRNA-transfected HeLa cells. SMILE siRNA-transfected HeLa
cells displayed a significantly decreased chymotrypsin-like activity
compared to control siRNA-transfected cells (Figure 3,
*p=0.0313, Wilcoxon signed rank test). The findings of SMILE
interaction with PDIA3 in the endoplasmic reticulum, together
with SMILE modulation of transcripts involved in protein
catabolism and chymotrypsin-like activity of the proteasome,
suggest that SMILE may play a role in the control of proteolysis via
proteasome activity in the endoplasmic reticulum.
SMILE silencing does not affect cell growth but sensitizes
HeLa cells to ER stress
To more precisely study the effects of SMILE siRNA on cell
morphology, we performed electronic microscopy (EM) analysis in
SMILE siRNA and control siRNA-transfected cells. At an ultra
structural level, resting control siRNA-transfected cells displayed a
well-conserved overall architecture and organization. In contrast,
SMILE down-regulation induced ER hypertrophy associated with
a reduction of free ribosomes as compared to control cells (Fig. 4A
and B), suggesting that down-regulation of SMILE affects ER
function. Improperly folded protein degradation is a main actor of
ER stress via accumulation in the ER lumen. We thus
hypothesized that down-regulation of SMILE would sensitize cells
to the effect of Bortezomib (a 26S proteasome inhibitor inducing
ER stress). To address this question, we performed EM analysis in
SMILE siRNA and control siRNA transfected HeLa cells treated
with Bortezomib (20 nM for 24 h). As expected, Bortezomib
treatment induced ER hypertrophy in control cells (Figure 4C).
SMILE siRNA-transfected cells displayed an increased sensitivity
to Bortezomib with dramatic ER enlargement and vacuolization
and features of cellular disorganization and injury (Figure 4D).
These results suggest that SMILE down-regulation sensitizes cells
to ER stress.
Figure 2. Confocal laser analysis of PDIA3 (red) and SMILE
(green) proteins in cultured human odontoblasts. (A) PDIA3
labeling is localized in the endoplasmic reticulum. (B) SMILE labeling is
mainly present in vesicles and in some cells in the reticulum area. (C)
Merged picture showing the colocalization of PDIA3 and SMILE in the
endoplasmic reticulum. (D) A higher magnification of (C) showing
yellow dots in the endoplasmic reticulum. Bar in A is 40 mm. Bar in D is
10 mm.
doi:10.1371/journal.pone.0019321.g002
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and impairs long-term cell survival
To further determine if SMILE siRNA-mediated down-
regulation sensitizes HeLa cells to ER stress and if this is mediated
by proteasome activity, we monitored the effects of different drugs
inducing various stresses on HeLa cells after SMILE silencing in
long-term cultures (7 days). Besides Bortezomib, we used
Thapsigargin, a blocker of sarco/endoplasmic reticulum Ca
2+/
ATPase, which induces proteasome-independent ER toxicity.
Moreover, Etoposide, an inhibitor of topoisomerase II, that
induces cytotoxicity in an ER-independent manner, was also used
as a negative control. We compared the effects of a seven-day,
dose-response treatment with these drugs in HeLa cells transfected
with either SMILE siRNA or control siRNA in clonogenic survival
assays. As illustrated in Figure 5A, without any treatment, HeLa
cells transfected with SMILE siRNA displayed a decreased
number of cell clusters compared to cells transfected with control
siRNA (**p=0.0045, Mann-Whitney test). Bortezomib, Thapsi-
gargin and Etoposide induced a dose-dependent decrease in the
cluster numbers in both cells transfected with control or SMILE
siRNA, showing that these drugs are effective (Significance of
p=0.0001 for the dose-effects of Bortezomib, Thapsigargin and
Etoposide, Two-way ANOVA, data not shown) We observed that a
large dose of Bortezomib induced a significantly greater decrease
in the number of clusters constituted by SMILE siRNA-transfected
cells compared to control siRNA-transfected cells. These data
confirmed the electronic microscopy and suggested that cells
lacking SMILE are more sensitive to the toxic effect of an ER
stressor that blocks proteasome activity than control siRNA-
transfected cells (Figure 5B, *p=0.0317, Mann-Whitney test).
Compared to Bortezomib effects, control and SMILE siRNA-
transfected cells treated with Thapsigargin or Etoposide displayed
the same decrease in the number of clusters, indicating a similar
toxicity of these two drugs on cells lacking SMILE mRNA
(Figure 5C and 5D). These results suggest that HeLa cells lacking
SMILE mRNA are more sensitive to ER stress dependent on
proteasome activity blockade compared to other stresses.
Down-regulation of SMILE/TMTC3 induces upregulation
of XBP-1 transcription
In order to determine whether there is a direct link between
SMILE down-regulation and ER stress, we further tested XBP-1
expression in HeLa cells transfected with SMILE siRNA and
treated 6 h with 20 nM Bortezomib. XBP-1 is a stress response
protein activated upon exposure to ER stress and allowing
transcription of genes of the Unfolded Protein Response. SMILE
mRNA down-regulation resulted in significant XBP-1 transcript
overexpression after Bortezomib treatment (Figure 6A,
*p=0,0156, Wilcoxon signed rank test). This experiment was
confirmed on primary cells (human keratinocytes). SMILE mRNA
expression was checked by RT-PCR and decreased by almost
70% in resting keratinocytes transfected with SMILE siRNA as
compared to cells transfected with Stealth RNAi negative control
Low GC (*p=0.0418, Wilcoxon signed rank test, mean replicate
values of four independent experiments, data not shown). As shown
in figure 6B, SMILE transcript silencing and 6 h-Bortezomib
Table 1. Function enrichment of down-regulated transcripts in SMILE siRNA-transfected cells.
GO NUMBER GO CATEGORY TOTAL GENES CHANGED GENES p-value
1 GO:0032940 secretion by cell 136 14 0.000550
2 GO:0019752 carboxylic acid metabolic process 303 22 0.002199
3 GO:0006082 organic acid metabolic process 305 22 0.002388
4 GO:0045045 secretory pathway 114 11 0.003544
5 GO:0006508 proteolysis 378 25 0.003965
6 GO:0016192 vesicle-mediated transport 334 22 0.007058
7 GO:0046903 secretion 182 14 0.008350
8 GO:0044255 cellular lipid metabolic process 345 22 0.010152
9 GO:0044260 cellular macromolecule metabolic process 1958 91 0.010267
10 GO:0030163 protein catabolic process 168 13 0.010346
11 GO:0006066 alcohol metabolic process 190 14 0.011947
12 GO:0043285 biopolymer catabolic process 234 16 0.014630
13 GO:0019538 protein metabolic process 2039 93 0.015656
14 GO:0032787 monocarboxylic acid metabolic process 141 11 0.016685
15 GO:0006629 lipid metabolic process 407 24 0.018131
16 GO:0044267 cellular protein metabolic process 1906 87 0.019677
17 GO:0006753 nucleoside phosphate metabolic process 126 10 0.019712
18 GO:0009117 nucleotide metabolic process 126 10 0.019712
19 GO:0044262 cellular carbohydrate metabolic process 189 13 0.025232
20 GO:0055086 nucleobase nucleoside and nucleotide metabolic process 138 10 0.034312
21 GO:0006807 nitrogen compound metabolic process 226 14 0.044629
22 GO:0009308 amine metabolic process 206 13 0.045829
23 GO:0009057 macromolecule catabolic process 291 17 0.046136
24 GO:0009056 catabolic process 448 24 0.048405
doi:10.1371/journal.pone.0019321.t001
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tion (**p=0.0078, Wilcoxon signed rank test). Interestingly,
SMILE transcript silencing without proteasome blockade also
induced an increase in XBP-1 transcription in keratinocytes
(p=0.0547, Wilcoxon signed rank test), suggesting that epithelial
primary cells are more susceptible to SMILE transcript silencing
alone and that SMILE transcript modulation directly impacts ER
stress responses.
Discussion
Although immunological tolerance has been achieved in animal
models, its translation into the clinic has not yet been feasible and
remains highly experimental in both non human primates and
humans. Nevertheless, compelling evidence has accumulated
showing that some transplant recipients permanently accept their
kidney or liver grafts in the absence of immunosuppressive therapy
[5,10,11,12]. Along these lines, during the last decade, significant
efforts have been made among the transplant community
(Reprogramming the Immune System for Establishment of Tolerance and
Indices of Tolerance) in Europe [11] and (Immune Tolerance Network)i n
the US [12] to identify biological signatures of ‘‘operational
tolerance’’.
We previously identified a list of 49 genes which were able to
discriminate operationally tolerant patients from other cohorts of
transplant patients [6]. SMILE/TMTC3 was one of the genes
found to be differentially expressed in the blood from operationally
tolerant patients compared to stable and rejecting patients and
whose function was unknown. Confirming the latter study, a
differential expression of SMILE transcripts was additionally
reported by the team of Newell et al. between a cohort of 25
operationally tolerant patients and stable patients (data available
on Gene Expression Omnibus Datasets under reference
GSE22229) [12]. The modulation of SMILE transcripts in the
blood of operationally tolerant patients and patients with chronic-
antibody mediated rejection patients and the independence of
SMILE transcript levels to external confounding factors suggest
that SMILE may have a potential implication in controlling graft
status. However, as there is no described cellular or clinical role for
SMILE, it is not yet known if SMILE has an active role in the
establishment of tolerance, or if this molecule is a passive
biomarker of tolerance. Thus, the present study was conducted
to further explore the potential functions of SMILE. We report
that SMILE interacts with PDIA3, which has a crucial role in
glycoprotein folding in endoplasmic reticulum [22], in the loading
of peptide on MHC class I in endoplasmic reticulum [13] and
which is overexpressed during ER stress. The interaction between
SMILE and PDIA3 was initially identified in a yeast Two-Hybrid
screen and confirmed by immunohistochemistry showing an
endoplasmic reticulum colocalization of the two molecules. We
also showed here that siRNA-mediated SMILE knock-down in
HeLa cells induces a decrease in several types of transcripts
involved in protein catabolism and proteolysis. Among these
transcripts we found that several immunoproteasome subunits
Table 2. List of the genes involved in proteolysis function (GO:0006508).
GENE NAME TOTAL GENES CHANGED GENES p-value FOLD CHANGE
1 CASP9 378 25 0.00396506 0.272137
2 SCRN1 378 25 0.00396506 0.825240
3 LONRF1 378 25 0.00396506 0.650918
4 ABHD4 378 25 0.00396506 0.553770
5 MMP9 378 25 0.00396506 0.813543
6 CRADD 378 25 0.00396506 0.584922
7 YME1L1 378 25 0.00396506 0.702569
8 SRGN 378 25 0.00396506 0.535910
9 NLN 378 25 0.00396506 0.706486
10 PSMB10 378 25 0.00396506 0.603119
11 UBE2N 378 25 0.00396506 0.587638
12 LAP3 378 25 0.00396506 0.834631
13 C1S 378 25 0.00396506 0.489116
14 CTSC 378 25 0.00396506 0.451692
15 PSMB1 378 25 0.00396506 0.756877
16 PCSK1 378 25 0.00396506 0.347323
17 PSMB9 378 25 0.00396506 0.302844
18 RNF11 378 25 0.00396506 0.413019
19 USP48 378 25 0.00396506 0.651608
20 FBXO21 378 25 0.00396506 0.441026
21 USP40 378 25 0.00396506 0.767610
22 UBE2H 378 25 0.00396506 0.576337
23 CPA4 378 25 0.00396506 0.690188
24 USP18 378 25 0.00396506 0.555519
25 OMA1 378 25 0.00396506 0.539055
doi:10.1371/journal.pone.0019321.t002
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SMILE exerts its function via the proteasome pathway. As
expected, proteasome activity assessed by chymotrypsin-like
activity was decreased in SMILE siRNA-transfected cells as
compared to control siRNA-transfected cells. These results suggest
that SMILE might have a role in protein folding and/or
degradation, exerting its function via the proteasome pathway.
Incorrect folding of proteins in cells is counteracted by the
Unfolded Protein Response (UPR). If UPR is not sufficient to
process protein overload in the ER, this pathway can be
deleterious and lead to cell apoptosis or autophagy [14,15]. To
assess the involvement of SMILE in ER stress responses and
protein catabolism, we treated SMILE siRNA-transfected cells
with various stressors, including Bortezomib, a proteasome
inhibitor. SMILE down-regulation and/or Bortezomib treatment
induced dramatic ER enlargement and features of cellular injury.
Furthermore, Bortezomib inhibition of long-term cellular growth
was strongly enhanced in SMILE siRNA-transfected cells.
Interestingly, the toxicity of Thapsigargin, an ER stressor whose
effects are unrelated to proteasome inhibition, was independent of
the level of SMILE expression on the cell response to stress. Thus,
SMILE transcript inhibition increased sensitivity to ER stress
dependent on protein overload induced by the proteasome
inhibitor Bortezomib. One arm of the UPR response involves
the spliced transcript XBP-1. In this study, we showed that SMILE
silencing directly increased XBP-1 transcript expression after
6 hours of Bortezomib treatment. Altogether these data suggest
that in HeLa cells, proteasome pharmacological inhibition and
SMILE silencing act in a synergistic way, likely by blocking protein
degradation or modification for degradation. As suggested in the
literature, blockade of protein degradation induces accumulation
of misfolded proteins in the ER and leads to ER stress, and thus to
XBP-1 overexpression [16].
Interestingly, a recent study by Fasanaro et al. reported that
SMILE/TMTC3 mRNA is inversely modulated after miR-210
over-expression or inhibition [17]. Of note, miR-210 expression is
induced by hypoxia, which was shown to induce UPR as a pro-
survival mechanism in tumor cells [18]. One of the responses to
hypoxia via miR-210 involves indirect targets implicated in amino
acid catabolism [17]. Our results in proteolysis suggests that
SMILE may be part of the response to hypoxia - and thus to ER
stress - via miR-210 or not. Moreover, our DNA chip analysis
revealed that SMILE down-regulation in HeLa cells affects the
secretory pathway as well as vesicle-mediated transport
(GO:0045045 and GO:0016192). Interestingly, membrane traf-
ficking is one of the functions that is modified in response to miR-
210 modulation and that could be set off by hypoxia, according to
Fasanaro et al. [17]. Thus, this work supports our results for
SMILE having a role in proteolysis and being potentially an actor
of the ER stress response. Regarding the fact that SMILE was
discovered in PBMCs of patients, it may play a direct role in the
immune cell physiology in long-term graft function. The role of
the UPR, and particularly of XBP-1, in the mammalian immune
system [19,20] and in inflammation has been clearly demonstrated
[21]. Indeed, the stress response is involved in a variety of immune
cells such as dendritic cells [20,22], macrophages [23] or B cells
[24,25,26] and depend on the UPR and notably XBP-1 for their
development and/or function. This could be of potential interest
given the recent studies showing that operationally tolerant
patients display a particular B cell profile highlighting a possible
abnormal B cell differentiation process in these patients
[11,12,27,28]. A recent paper have reported that the STAT3/
IL-6 pathway, that has also been shown to be involved in ER stress
[29,30], is activated neither in operationally tolerant patients nor
in rejecting patients [31]. These results that do not confort our
hypothesis may be due to the fact that the STAT3/IL-6 pathway
is not the only signaling pathway reflecting UPR activity, and the
absence of its activity in operationally tolerant or rejecting patients
may not preclude the absence of UPR activity in the PBMCs of
these patients. Growing evidence suggests that the selectivity of
Bortezomib for myeloma cells may be explained by an increased
susceptibility of myeloma cells to ER stress-induced apoptosis [32].
In addition, Bortezomib is not only selective for cancerous cells, as
recent studies showed that primary B cells, that are largely
dependent on UPR and proteasome activity to produce antibod-
ies, are sensitive to Bortezomib. This treatment was shown to
decrease donor-specific antibodies in renal transplant patients in
recent studies [33,34]. Our results showed that primary cells are
far more sensitive to SMILE transcript silencing than HeLa cells,
as there was no need for Bortezomib treatment to induce XBP-1
overexpression in SMILE-silenced keratinocytes. These results
suggest that SMILE transcript modulation in immune cells may
have an impact on the function of the cell and particularly on its
response to ER stress. They allow a function in ER stress response
to be attributed to this molecule, which was previously unknown.
Moreover, it opens up new perspectives about ER stress and graft
immune regulation, given the role of the ER stress response in
immune cells. SMILE may have a potential role in these cell types
related to the emerging role of the ER stress response in
transplantation. We also envisage a role for SMILE in the graft
itself, in addition to recent works showing ER stress emerging as an
actor at the graft level [35,36,37].
To conclude, further studies are needed to analyze the effects of
SMILE transcript modulation in immune cells. This molecule and
Figure 3. Chymotrypsin-like activity of the proteasome in
SMILE siRNA-transfected Hela cells. The luminescent signal
measured in arbitrary units (AU) is proportional to the amount of
proteasome activity and is decreased in SMILE siRNA versus control
(C- siRNA) siRNA-transfected Hela cells (*p=0.0313, Wilcoxon signed
rank test).
doi:10.1371/journal.pone.0019321.g003
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relevance in the field of organ transplantation.
Materials and Methods
Patients
The study was performed on 42 blood samples. All patients and
healthy volunteers (HV) who participated in this study signed an
informed consent and the study was approved by the University
Hospital Ethical Committee (Nantes, France). The clinical
parameters of these patients are described in detail in Table S1.
N Patients under standard immunosuppressive therapy with stable
graft function (STA; n=9; patients with Cockroft creatinine
clearance .40 mL/minand proteinuria ,1 g/24 h) for at least
3 years with donor-specific antibodies for 2 out of 9 patients. No
biopsies were available for these patients because they presented
no deterioration of graft function (certain cDNA samples were
prepared by TcLand Expression S.A., Nantes, France). These
patients were under anti-metabolites (mycophenolate mofetil or
azathioprine), calcineurin inhibitors (Cyclosporin A or FK506)
and/or steroids.
N Operationally tolerant patients: patients with stable graft
function (TOL; n=8; Cockroft creatinine clearance
.40 mL/min and proteinuria ,1 g/24 h) for at least 1 year
(median 12.5 years, range 5–30 years) without immunosup-
pressive treatment. Immunosuppressive treatment was stopped
due to non compliance (n=6), post-transplant lymphoprolif-
erative disorder (n=1) or calcineurin inhibitor toxicity (n=1).
No biopsies were available for these patients since biopsy was
refused by our Centre’s Ethical Committee.
N Patients with chronic antibody mediated rejection: Patients
under standard immunosuppressive therapy with biopsy-
proven chronic antibody-mediated rejection (transplant glo-
merulopathy, positive for C4d and anti-donor HLA antibodies)
(CAMR; n=14) according to the updated Banff classification
criteria [38]. Chronic AMR was diagnosed on biopsies
performed in the context of a progressive deterioration of
renal function (Cockroft creatinine clearance ,40 mL/min
and/or proteinuria .1 g/24 h).
Figure 4. Endoplasmic reticulum hypertrophy in SMILE siRNA-transfected HeLa cells. Control (A) and SMILE (B) siRNA transfected HeLa
cells cultured 24 h with RPMI+vehicle (DMSO). Endoplasmic reticulum vacuolization in HeLa cells treated 24 h with 20 nM Bortezomib and
transfected with SMILE siRNA (D) compared to cells transfected with control siRNA (C).
doi:10.1371/journal.pone.0019321.g004
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Peripheral blood from healthy volunteers and patients was
collected in EDTA Vacutainers, and PBMC were separated by
density centrifugation using Lymphosep, lymphocyte separation
media (Bio West, Nuaille, France). PBMC were stored in TRIzol
(Invitrogen, Cergy Pontoise, France) at 280uC until use.
RNA Extraction and Preparation of cDNA
RNA was extracted from human PBMC, HeLa cells and
keratinocytes using the TRIzol method (Invitrogen) according to
the manufacturer’s instructions. Genomic DNA was removed by
DNase treatment (Roche, Indianapolis, IN). RNA concentration
was calculated using a Nanodrop ND1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE). RNA was reverse
transcribed into cDNA using polydT oligonucleotide and Maloney
leukemia virus reverse transcription (Invitrogen).
Real-Time Quantitative PCR
Real-time quantitative PCR was performed in an Applied
Biosystems GenAmp 7700 or 7900 sequence detection system
(Applied Biosystems, Foster City, CA) using a commercially
available primer and probe set for human SMILE/TMTC3
(Applied Biosystems; Hs00699202_m1) and XBP-1 (Applied
Biosystems; Hs00231936_m1). The housekeeping gene hypoxan-
thine phosphoribosyl transferase (HPRT, Applied Biosystems;
Hs99999909_m1) was used as an endogenous control to normalize
RNA starting quantity. Relative expression between a given
sample and a reference sample was calculated according to the
2
2ddCt method after normalization to HPRT with results
expressed in arbitrary units.
Culture and treatment of Human cervical cancer cell line
(HeLa) and keratinocytes
Human cervical cancer cells HeLa were cultured in RPMI 1640
medium (Invitrogen, Cergy Pontoise, France) supplemented with
10% fetal bovine serum, 1% penicillin-streptomycin, 1% gluta-
mine, 1% Hepes, 1% non-essential amino acids and 1% sodium
pyruvate. Keratinocytes were kindly provided by Dr. Halary
(INSERM UMR 643, Nantes, France) and cultured in Keratino-
cyte Growth Medium (#C-20011, PromoCell, Heidelberg,
Germany). SMILE knockdown was achieved with specific small
interfering RNA (TMTC3 Stealth RNAi
TM siRNA, #
HSS136195), Lipofectamine
TM RNAiMAX for HeLa cells and
Lipofectamine
TM 2000 transfection reagent+OptiMEM for kera-
tinocytes, purchased from Invitrogen. Cells were transfected using
the manufacturer’s protocol.
Yeast two-hybrid screen
Yeast two-hybrid screening was performed by Hybrigenics
Services SAS, France (http://www.hybrigenics-services.com). The
coding sequence for aa 1–230 of PDIA3 (GenBank accession
number gi: 67083697) was PCR-amplified and cloned into pB28
as a C-terminal fusion to LexA (N-LexA-PDIA3-C). The construct
was checked by sequencing the entire insert and used as a bait to
screen a random-primed human brown adipocyte cDNA library
constructed into pP6. pB28 and pP6 derive from the original
pBTM116 [39] and pGADGH [40] plasmids, respectively. 150
million clones (15-fold the complexity of the library) were screened
using a mating approach with Y187 (mata) and L40DGal4 (mata)
yeast strains as previously described [41] and positive clones were
selected on a medium lacking tryptophan, leucine and histidine,
and supplemented with 0.5 mM 3-aminotriazole to handle bait
autoactivation. The prey fragments of the positive clones were
amplified by PCR and sequenced at their 59 and 39 junctions. The
resulting sequences were used to identify the corresponding
interacting proteins in the GenBank database (NCBI) using a
fully automated procedure. A confidence score (PBS, for Predicted
Biological Score) was attributed to each interaction as previously
described [8].
Preparation of odontoblast culture
Dental pulps were obtained from healthy human third molar
germs (from 14- to 16-year-olds) extracted for orthodontic reasons
with the informed consent of the participants and their parents, in
accordance with the French Public Health Code and following a
protocol approved by the local ethics committee. Pulps were
processed for cultured odontoblast-like cells as described previ-
ously [42] and treated during 24 hours with Bortezomib 20 nM
(Millennium Pharmaceuticals, Inc, Cambridge, United Kingdom).
Immunohistochemistry
Odontoblast cell cultures were fixed in 4% paraformaldehyde-
0,025% saponin-PBS for 30 min at 4uC, then rinsed in PBS-
0,025% saponin-2 mg/ml bovine serum albumin-0,1 M lysine
HCl at 4uC. Intracellular detection of proteins was promoted by
the permeabilizing effect of saponin. Cultures were then reacted
for double staining with anti-PDIA3 (# HPA003230, Sigma-
Aldrich, France) and anti-smile (# ab81473, Abcam, France)
antibodies. Subsequently, the cultures were rinsed, incubated with
goat anti-mouse Alexa Fluor 594 and goat anti-rabbit 488
Figure 5. Transfected HeLa cell behavior when undergoing
endoplasmic reticulum stress. Graphic representations of viable cell
cluster numbers in clonogenic assays. (A) Absolute number of clusters
of cells transfected with control siRNA (white bars) compared to cells
transfected with SMILE siRNA (black bars) (**p=0.0045, Mann-Whitney
test). Absolute number of clusters of cells transfected with control
siRNA (white bars) compared to cells transfected with SMILE siRNA
(black bars) and treated with 5 nM Bortezomib (B, *p=0.0317, Mann-
Whitney test), 100 nM Thapsigargin (C, p=0.3939, Mann-Whitney test)
or 180 nM Etoposide (D, p=0.4, Mann-Whitney test).
doi:10.1371/journal.pone.0019321.g005
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by scanning laser confocal microscopy (Zeiss LSM510, Zeiss, Le
Pecq, France) with 406/1.3 oil immersion objectives. PDIA3 was
assigned red, and Smile was assigned green with the laser scanning
software. Negative controls were carried out by omission of the
primary antibodies or by incubation with normal mouse or rabbit
IgG (data not shown). Figures from the Z-stack were processed in
Adobe Photoshop 6.0 (Adobe Systems,San Jose, CA, USA).
Transmission Electron Microscopy on transfected and
drug-treated Hela cells
SMILE and control siRNA transfected HeLa cells at the 3rd
day of culture were fixed in cacodylate buffered 4% glutaralde-
hyde for 1 h at 4uC, washed in buffer and post-fixed in cacodylate
buffered 2% osmium tetroxide for 1 h at room temperature. Cells
were dehydrated in increasing concentrations (from 50u to 100u)o f
ethanol and embedded in Epon. Sections (70 nm-thick) were cut
with an Ultracut E ultramicrotome (Leica Microsystems GmbH,
Wetzlar, Germany), mounted on copper grids, stained with the
Reynolds method and observed on a JEM 1010 electron
microscope (Jeol LTD, Tokyo, Japan) at a voltage of 80 kV.
Gene expression analysis in HeLa cells using DNA chips
RNA samples representing two independent experiments from
HeLa cells transfected 24 hours with negative control or SMILE
siRNA and activated or not with 20 mM PMA (Phorbol 12-
myristate 13-acetate) for 6 hours were submitted for analysis. After
checking RNA quality, 500 mg of total RNA for each sample were
prepared with the Agilent Quick Amp Labeling Kit following the
one-color manufacturer’s protocol. Each sample was hybridized to
a whole human genome microarray (4644 K Agilent) following
the manufacturer’s instructions. After scanning, data were
extracted with Feature Extraction (Agilent Technologies) were
normalized (lowess function in R [43]) and then, negative control
spots and background signal were removed. Significance Analysis
of Microarrays (SAM) [44] was applied to identify transcripts
differentially expressed between SMILE siRNA and control
siRNA-transfected cells. For each analysis, we arbitrarily fixed
the false discovery rate (FDR) at less than 0.5%. To assess the
biological significance of the differentially expressed genes
identified with SAM, GOminer software [44,45] was used to
identify the over-represented GO ontology (GO) categories. Only
GO categories among the biological process ontology
(GO:0008150) were analyzed, and we selected GO categories
with enrichment p-values inferior to 0.05, and categories with at
least 10 genes. All microarray data is MIAME compliant and the
raw data has been deposited in a MIAME compliant database, the
Gene Expression Omnibus Datasets. The complete list of the
probes used and expression analysis has been submitted to Gene
Expression Omnibus GEO # GSE21886.
Proteasome-Glo
TM Cell-Based Assay
HeLa cells were seeded in 6-well plates at a density of 8610
5
cells per well for 24 h and transfected for 48 h with control and
SMILE siRNA as described above. The chymotrypsin-like activity
of transfected cells was then assayed with the Proteasome-Glo
TM
Cell-Based Reagent (Promega, Charbonnie `res Les Bains, France)
according to manufacturer’s protocol. Luminescence was read
with a VICTOR
TM X Multilabel Plate Reader (Perkinelmer,
Massachusetts, USA).
Clonogenic survival assays
Control and SMILE siRNA transfected HeLa cells were seeded
in 6-well plates at a density of 500 cells per well and exposed to
increasing concentrations of Bortezomib (1.25 nM, 2.5 nM or
5 nM from a 0.1 mg/ml start solution, Millennium Pharmaceu-
ticals, Inc, Cambridge), Thapsigargin (25 nM, 50 nM, 100 nM
from a 1 mM start solution, Sigma-Aldrich) or Etoposide (90 nM,
Figure 6. XBP-1 mRNA expression in control versus SMILE siRNA-transfected cells treated or not with Bortezomib 20 nM. (A) XBP-1
transcripts are significantly increased in SMILE siRNA-transfected HeLa cells after 6 h treatment with Bortezomib at 20 nM (*p=0.0156, Wilcoxon
signed rank test). (B) XBP-1 transcripts are also significantly increased in SMILE siRNA-transfected keratinocytes after 6 h treatment with Bortezomib at
20 nM (**p=0.0078, Wilcoxon signed rank test), and are increased in SMILE siRNA-transfected keratinocytes without treatment (p=0.0547, Wilcoxon
signed rank test).
doi:10.1371/journal.pone.0019321.g006
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24 hours. Controls were performed with vehicle only: H2O for
Bortezomib and DMSO for Thapsigargin and Etoposide. Then,
the drug/medium was removed and cells were allowed to incubate
in fresh medium under normal conditions for 7 days. After
incubation, cells were fixed with 10% methanol–10% acetic acid
and stained with a 0.4% solution of crystal violet. Plating
efficiencies were determined for each treatment and normalized
to untreated cells. Error bars represent SEM.
Statistical Analyses
The nonparametric Mann-Whitney test, the nonparametric
Wilcoxon matched pairs test and the nonparametric Kruskal-
Wallis test were performed when appropriate. Values of *p,0.05,
**p,0.01 and ***p,0.001 were considered as significant. ROC
curve analysis was performed to determine the cutoff point of
SMILE mRNA in blood that yielded the highest combined
sensitivity and specificity in diagnosing operational tolerance. The
statistical method was devoted to the analysis of the diagnostic
properties of SMILE, and the theory of ROC (receiver operating
characteristic) curves was applied. More information about this
method is available in SD Experimental Procedures.
A statistical analysis was also made in order to study the
relationship between SMILE mRNA expression in a cohort of 164
stable patients and different clinical factors that could influence the
diagnostic power of this biomarker. SMILE distribution was
normalized with a logarithmic transformation and SMILE log-
values were predicted thanks to a multiple linear regression model.
Supporting Information
Figure S1 SMILE mRNA profile in renal transplant patients.
The quantity of SMILE mRNA transcripts is increased in PBMC
of operationally tolerant patients (TOL, n=8) compared to
patients with stable graft function under standard immunosup-
pressive therapy (STA, n=164, **p,0.01) and deteriorating graft
function under standard immunosuppressive therapy with biopsy-
proven chronic antibody-mediated rejection (CAMR, n=19,
*p,0.01) (**p=0.0052, Kruskal-Wallis test).
(TIF)
Figure S2 ROC curve analysis measuring the ability of SMILE
mRNA quantity to correctly distinguish operationally tolerant
patients from patients with chronic antibody-mediated rejection.
(TIF)
Figure S3 Analysis of SMILE association with continuous
explicative variables in a group of 164 stable kidney transplant
recipients.
(TIF)
Figure S4 Analysis of SMILE association with continuous
qualitative variables in a group of 164 stable kidney transplant
recipients.
(TIF)
Figure S5 Graphic representation of the domain architecture of
PDIA3 (A) and SMILE (B). The blue boxes represent the full-
length proteins. The pink rectangle shows the bait fragment of
PDIA3 which was used for the yeast two-hybrid (Y2H) screen. The
orange rectangle represents the smallest interacting domain (SID)
of SMILE. The black lines show the seven independent prey
fragments of SMILE that were identified in the Y2H screen using
PDIA3 as bait. Functional and structural domains are indicated by
colored rectangles: yellow, signal peptides; red, transmembrane
domains; magenta, coiled-coil domains; grey: predicted functional
domains (PFAM database). The numbers indicate the amino acid
positions of the corresponding domains.
(TIF)
Figure S6 SMILE transcript level analysis in non-transfected
HeLa cells (HeLa alone), control siRNA-transfected HeLa cells
(C- siRNA) and SMILE siRNA-transfected HeLa cells (SMILE
siRNA) (***p=0.0002, Mann-Whitney test).
(TIF)
Table S1 Patients included in analysis of PBMCs.
(XLS)
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